Lacy Brian E
Senior Associate Consultant, Mayo Clinic, Jacksonville, FL. Email:
Am J Manag Care. 2019 Mar;25(4 Suppl):S55-S62.
Chronic idiopathic constipation is a functional bowel disorder characterized by difficult, infrequent, and/or incomplete defecation, affecting 35 million adult Americans, resulting in more than millions of physician visits annually. Symptoms of constipation vary from patient to patient and impact all age groups and patient populations in the United States. The definition of constipation was previously not well specified, beyond stool frequency, and has been revised to incorporate the patient perspective and experience in addition to specific criteria created by the Rome Foundation. In the absence of red-flag (alarm) symptoms, and with a normal physical (including rectal) examination, patients can initially be empirically treated for their symptoms of chronic constipation assuming adequate follow-up is arranged. Unfortunately, both patients and healthcare providers have documented unmet needs with currently available therapeutic options, thus prompting research for new agents with novel mechanisms of action that are both efficacious and safe.
慢性特发性便秘是一种功能性肠道疾病,其特征为排便困难、次数少和/或排便不完全,影响着3500万美国成年人,每年导致数百万人次就医。便秘症状因人而异,影响美国所有年龄组和患者群体。以前,除了大便频率外,便秘的定义并不明确,现在已进行修订,除了罗马基金会制定的具体标准外,还纳入了患者的观点和体验。在没有警示(报警)症状且体格检查(包括直肠检查)正常的情况下,若安排了充分的随访,患者最初可根据经验接受慢性便秘症状的治疗。不幸的是,患者和医疗服务提供者都记录了现有治疗方案未满足的需求,因此促使人们研究具有新作用机制的既有效又安全的新药物。